why choose us

First received: July 04, 2023

Clinical Trial: Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8

Study Status: Completed

Recruit Status: RECRUITING

Condition: Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: SPECT Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 ([99mTc]Tc- DB8) in Prostate Cancer and Breast Cancer Patients

Brief Summary: The study should evaluate the biological distribution of 99mTc-DB8 in patients with prostate cancer and breast cancer.The primary objective are:To assess the distribution of [99mTc]Tc- DB8 in normal tissues and tumors at different time intervals.To evaluate dosimetry of [99mTc]Tc- DB8.To study the safety and tolerability of the drug [99mTc]Tc- DB8 after a single injection in a diagnostic dosage.The secondary objective are:1. To compare the obtained [99mTc]Tc- DB8 SPECT imaging results with the data of CT…

Read more